Microbiome genes on the move
Largest metagenomic view of the developing world uncovers “mobile genes” that reveal how culture shapes the human microbiome.
New clue to how lithium works in the brain
Biologists find a possible explanation for why the drug helps bipolar patients.
Study sheds light on role of mutations in metastasized cancer
Researchers identify genes that mutate in endometrial cancer, create a family tree describing the evolutionary history of the disease.
Mapping molecular neighborhoods
Associate Professor Ernest Fraenkel uses biological network modeling to identify new targets for disease.
A strategy for “convergence” research to transform biomedicine
Report calls for more integration of physical, life sciences for needed advances in biomedical research.
Feng Zhang named 2016 Tang Prize laureate
Broad Institute/MIT scientist among three honored for CRISPR contributions.
Study: Molecular motors shape chromosome structure
By organizing chromosomes into many tiny loops, molecular motors play key role cell division.
New CRISPR system for targeting RNA
Scientists program C2c2, discovered in bacteria as a viral defense mechanism, to manipulate cellular RNA.
Scientists illuminate a hidden regulator in gene transcription
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Neuroscientists illuminate role of autism-linked gene
Loss of Shank gene prevents neuronal synapses from properly maturing.
Eric Lander wins faculty’s Killian Award
Biologist honored for his scientific leadership, pioneering work in genomics, and inspiring teaching.
New approach to genetic analysis yields markers linked to complex diseases
Study identifies new gene variants that may be targets for treating arrhythmia.
Controlling RNA in living cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Taking on melanoma, one cell at a time
In step toward personalized medicine, researchers are using single-cell analysis to unravel cancer’s secrets.
Reprogramming gut bacteria as “living therapeutics”
Daily doses of synthetic biotics developed by startup Synologic may sense, treat metabolic diseases.